Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Emerging Data of Additional SERDs in Metastatic Breast Cancer

February 4th 2025

Panelists discuss recent data on other selective estrogen receptor degraders (SERDs) and their implications in the treatment of HR+/HER2– breast cancer.

Clinical Findings of Elacestrant, an Oral SERD for ER+/HER2– Metastatic Breast Cancer

February 4th 2025

Panelists discuss the clinical findings of elacestrant, an oral selective estrogen receptor degrader (SERD), for the treatment of ER+/HER2– metastatic breast cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

February 3rd 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Dr Bardia on the FDA Approval of Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer

February 3rd 2025

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of Dato-DXd for pretreated, hormone receptor–positive, HER2-negative metastatic breast cancer.

A Road Map for Change Report Provides a Guide to Elevate Breast Cancer Care

February 3rd 2025

Coauthor of the Lancet Breast Cancer Commission report, Reshma Jagsi, MD, DPhil, details the 6 themes of the evidence-based plan aimed to address challenges in the field.

Impact of In-House Testing on Improved Cancer Care: Timely Decisions and Enhanced Treatment Accuracy

February 3rd 2025

Panelists discuss how in-house laboratory testing has demonstrated significant advantages in patient care through rapid turnaround times and immediate decision-making capabilities. Emergency departments have seen notably improved outcomes when critical tests like cardiac markers and blood gases are performed on-site, enabling faster treatment initiation for acute conditions. For example, rapid troponin testing in-house allows for immediate cardiac intervention decisions, while stat electrolyte panels enable quick medication adjustments for critical patients. Additionally, on-site therapeutic drug monitoring helps clinicians make real-time dosing modifications, which is particularly beneficial for antibiotics and anticoagulation therapy.

Enhancing Multidisciplinary Coordination and Treatment Planning Through In-House Testing

February 3rd 2025

Panelists discuss how in-house testing facilities significantly enhance multidisciplinary coordination by enabling rapid result turnaround and real-time treatment adjustments. This streamlined process facilitates immediate care planning among specialists, leading to faster clinical decisions and reduced wait times. Studies demonstrate that on-site testing correlates with improved patient outcomes through earlier interventions, decreased length of stay, and enhanced treatment monitoring, ultimately supporting more efficient and responsive patient care delivery.

The OncFive: Top Oncology Articles for the Week of 1/26

February 1st 2025

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer

January 31st 2025

Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.

The ADC OQY-3258 Demonstrates Early Efficacy in Multiple Breast Cancer Subtypes

January 30th 2025

OQY-3258 (ESG401) showed preliminary efficacy in multiple breast cancer subtypes, including TNBC and HR+/HER2- breast cancer.

Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer

January 29th 2025

Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences.

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

January 29th 2025

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.

Inavolisib Plus Palbociclib/Fulvestrant Shows OS Benefit in Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Breast Cancer

January 28th 2025

Inavolisib plus palbociclib/fulvestrant improved OS vs palbociclib/fulvestrant alone in PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.

The Current Treatment Landscape of Oral SERDs in Metastatic Breast Cancer

January 28th 2025

Panelists discuss their overall perceptions of oral selective estrogen receptor degraders (SERDs) and their impact on the treatment landscape and share their experiences with elacestrant in clinical practice.

Clinical Perspectives: Use of CDK4/6i After CDK4/6i

January 28th 2025

Panelists discuss potential treatment options for patients following progression on CDK4/6 inhibitors (i) in HR+/HER2– metastatic breast cancer.

Optimizing In-House Testing: Enhancing Efficiency for Timely Results and Treatment Decisions

January 27th 2025

Panelists discuss how in-house testing significantly reduces turnaround times by eliminating send-out delays and courier dependencies. This enables immediate sample processing, allowing for faster results delivery and prompt clinical decision-making. Health care facilities can optimize workflows through automated systems, clear communication protocols, and standardized testing procedures, minimizing bottlenecks between departments and facilitating quicker diagnosis and treatment initiation.

Implementing In-House Biomarker Testing: Rationale and Key Considerations

January 27th 2025

Panelists discuss how implementing in-house biomarker testing can significantly enhance patient care through faster turnaround times and streamlined decision-making processes. This approach reduces dependence on external laboratories while enabling more immediate clinical interventions. Key implementation considerations include staff expertise, quality control protocols, equipment costs, regulatory compliance, and testing volume to ensure operational efficiency and return on investment

ADCs in HER2-Low Breast Cancer: Insights From DESTINY-Breast04, TROPiCS-02, and TROPION-Breast02

January 22nd 2025

Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates.

Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance

January 21st 2025

David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.

Dr Zhang on the Efficacy of SIM0270 Plus Everolimus in ER+/HER2− Advanced Breast Cancer

January 21st 2025

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.